RedHill Biopharma raises ATM capacity to $2.59 million under Form F-3 limit
The October 13, 2026 prospectus supplement lets RedHill sell additional ADSs up to $2,587,409, within a $2,637,099 Form F-3 ceiling.
SEC filing
3 stories
The October 13, 2026 prospectus supplement lets RedHill sell additional ADSs up to $2,587,409, within a $2,637,099 Form F-3 ceiling.
SEC filing
RedHill said it funded a $12 million Rebyota and Clenpiq acquisition from Ferring using proceeds from its Talicia divestment, while advancing opaganib, RHB-204 and RHB-102 programs.
SEC filing
New filing adds royalty rates, supply terms, and clinical and market figures behind RedHill's $12 million acquisition from Ferring.
SEC filing